MedTrace Logo

Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus

NCT05268237 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-02-06

No results posted yet for this study

Summary

This is a phase Ib/IIa, single ascending dose study of the safety, tolerability and preliminary efficacy of sublingual (SL) Liraglutide in patients with type 2 diabetes mellitus (T2DM).

Conditions

  • Diabete Type 2

Interventions

DRUG

Liraglutide

Sublingual or subcutaneous liraglutide

DRUG

Placebo

Sublingual placebo

Sponsors & Collaborators

  • Chinese University of Hong Kong

    collaborator OTHER

  • Biolingus

    lead INDUSTRY

Principal Investigators

  • Elaine YK Chow · Chinese University of Hong Kong

  • Juliana CN Chan · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-25
Primary Completion
2025-12-31
Completion
2026-03-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05268237 on ClinicalTrials.gov